George Yancopoulos, Regeneron CSO (Lev Radin/Sipa USA/Sipa via AP Images)
Regeneron forges ahead in factor XI despite field’s mixed results
Regeneron will start a “broad” Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2 results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
